Resources Repository
-
ArticlePublication 2016Cost-Effectiveness of Collaborative Care for Depression and Comorbid Diabetes or CVD
This article, published in BMJ Open, presents an economic model that combines a decision tree …
This article, published in BMJ Open, presents an economic model that combines a decision tree and a Markov cohort model to investigate the long-term cost-effectiveness of collaborative care versus usual care for individuals with depression and comorbid diabetes and/or cardiovascular disease. Data from the COINCIDE trial informs the model input parameters. The COINCIDE trial is a randomized controlled trial of collaborative care versus usual care that enrolled 387 participants from 36 primary care general practices…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | State-Transition | Mental Health | Europe -
ArticlePublication 2016Prevention and Treatment of Cardiovascular Disease
This article, published in Cost Effectiveness and Resource Allocation, aims to assess the cost-effectiveness of …
This article, published in Cost Effectiveness and Resource Allocation, aims to assess the cost-effectiveness of prevention and treatment of ischemic heart disease (IHD) and stroke in an Ethiopian setting. Fifteen single interventions and sixteen intervention packages are assessed from a healthcare provider perspective. The results indicate that the escalating burden of CVD and its risk factors warrants timely action. Selected CVD intervention packages could be scaled up at a modest budget increase, but the level…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Health Systems | Sub-Saharan Africa -
ArticlePublication 2016Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons
This study assesses the health and economic impact of hepatitis C virus (HCV) screening and …
This study assesses the health and economic impact of hepatitis C virus (HCV) screening and treatment in U.S. prisons on the broader HCV epidemic. Employing an agent-based microsimulation model of HCV transmission and disease progression, data from published literature inform the analysis. The target populations include individuals in U.S. prisons and the general community over a 30-year timeframe, adopting a societal perspective. Interventions encompass risk-based and universal opt-out HCV screening in prisons, followed by treatment…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Microsimulation | Infectious Diseases | North America -
ArticlePublication 2016Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to …
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to the health service provider. Effective approaches to increase the implementation of guidance are needed. Since investment in activities that improve implementation competes for funding against other health generating interventions, it should be assessed in term of its costs and benefits. In 2010, the National Institute for Health and Care Excellence released a clinical guideline recommending natriuretic peptide (NP) testing in…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Health Outcomes | Operations Research | Health Systems | Clinical Care | Economics/Finance | Europe -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Priority Setting/Ethics | Benefit-Cost Analysis | Infectious Diseases | Mental Health | Health Systems | Economics/Finance | Global -
ArticlePublication 2016An Economic Evaluation of the PEN Program in Indonesia
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) …
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) introduced the Package of Essential Noncommunicable disease (PEN) interventions. Several countries, including Indonesia, implemented the PEN program. To assess the value of the investment in the current program, an economic evaluation of the program was conducted with collaboration between the Ministry of Health in Indonesia, the WHO, and the International Decision Support Initiative (iDSI). This study evaluated the delivery of…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Priority Setting/Ethics | Technology Assessment | Health Systems | Economics/Finance | Government/Law | Asia & Pacific -
ArticlePublication 2016Helmet Regulation in Vietnam: Impact on Health, Equity and Medical Impoverishment
This study performed a retrospective extended cost-effectiveness analysis simulation study of Vietnam's 2007 comprehensive motorcycle …
This study performed a retrospective extended cost-effectiveness analysis simulation study of Vietnam's 2007 comprehensive motorcycle helmet policy. Modeling results showed that following its introduction, the helmet policy likely prevented approximately 2,200 deaths and 29,000 head injuries, saved individuals US$18 million in acute care costs and averted US$31 million in income losses. From a societal perspective, such a comprehensive helmet policy would have saved $11 000 per averted death or $830 per averted non-fatal injury.
Cost-Effectiveness Analysis | Health/Medicine | Injuries/Accidents | Asia & Pacific -
ArticlePublication 2015Health Gains & Financial Risk Protection by Public Financing in Ethiopia: An ECEA
This article, published in the Lancet Global Health, aims to evaluate the health and financial …
This article, published in the Lancet Global Health, aims to evaluate the health and financial risk protection benefits of selected interventions that could be publicly financed by the government of Ethiopia. The authors used an extended cost-effectiveness analysis (ECEA) to assess the health gains (deaths averted) and financial risk protection afforded (cases of poverty averted) by a bundle of nine interventions that the Government of Ethiopia aims to make universally available. This approach incorporates financial…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Priority Setting/Ethics | Mathematical Models | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Health Systems | Policy/Regulation | Sub-Saharan Africa -
ArticlePublication 2015Cost-Effectiveness & Budget Impact of Hepatitis C Virus Treatment with Sofosbuvir & Ledipasvir in the U.S.
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic …
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic hepatitis C virus (HCV) infection compared to the old standard of care (oSOC). Using a microsimulation model based on HCV natural history, data from published literature, and a third-party payer perspective, the analysis considers treatment-naive and treatment-experienced HCV populations in the United States over a lifetime horizon. Sofosbuvir-based therapies are found to add 0.56 quality-adjusted life-years (QALYs) relative to oSOC,…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Microsimulation | Infectious Diseases | North America